



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 30/05/2019

To, The Company Secretary, Corporate Compliance Department, The National Stock Exchange of India Limited, Bandra Kurla Complex, Mumbai	To, The Company Secretary, Corporate Compliance Department, BSE Limited, Dalal Street, P.J. Tower, Mumbai
---	---

Sub: Submission of Audited Financial Results for the Quarter as well as year ended 31st March, 2019 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scripe Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Audited Financial Results for the quarter as well as year ended 31st March, 2019 **duly approved by the Board of Directors of the Company at its meeting held on today i.e. Thursday, 30th May, 2019** at the registered office of the Company together with Auditors Report thereon, Statements of Assets and Liabilities and declaration by the Managing Director of the Company pursuant to second proviso of Regulation 33(3) (d) of SEBI Listing Regulations, 2015.

Further, above results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.


The Results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net and extracts of the results shall also be published in Hindi and English News papers.

You are requested to take on record the above said financial results for your reference and record.

Thanking you,

Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
(DIN: 00028819)



Audited Financial Results of Quarter and Year Ended of 31st March, 2019
Biofil Chemicals and Pharmaceuticals Limited


11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March 2019

Statement of Audited Financial Results for the Quarter and Year ended 31st March 2019						(Amount in Lakhs except EPS)
Particulars	3 months ended (31/03/2019)	Preceding 3 months ended (31/12/2018)	Corresponding 3 months ended in the previous year (31/03/2018)	Audited for the year Ended March 31 2019	Audited for the year ended March 31 2018	
	Audited	Reviewed	Audited	Audited	Audited	
I Revenue from Operation						
II Other Income	247.44	1429.40	355.18	2312.85	1236.00	
	4.44	2.02	5.37	10.12	10.07	
III Total Revenue (I + II)	251.89	1431.42	360.55	2322.98	1246.07	
IV Expenses						
(a) Cost of materials consumed						
(b) Purchases of stock-in-trade	13.33	31.13	38.88	77.27	77.75	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	69.94	557.37	278.08	1904.95	991.06	
(d) Employee benefits expense	57.17	758.01	-85.80	17.04	-91.70	
(e) Finance Cost	26.93	20.91	31.89	89.22	72.93	
(f) Depreciation and Amortisation Expense	4.37	3.88	3.68	16.03	15.06	
(g) Other expenses	14.48	7.44	8.30	36.51	29.63	
Total expenses (IV)	52.04	23.37	66.03	122.12	92.53	
V Profit/ (Loss) before exceptional items and tax (III-IV)	238.25	1402.10	341.05	2263.15	1187.25	
VI Exceptional Items	13.63	29.31	19.49	59.83	58.82	
VII Profit/ (Loss) before tax (V - VI)	0.00	0.00	0.00	0.00	0.00	
VIII Tax expense:	13.63	29.31	19.49	59.83	58.82	
(1) Current tax						
(2) Deferred tax Credit/(Charge)	11.60	0.00	11.75	11.60	11.75	
IX Profit/(Loss) for the period from continuing operation (VII-VIII)	0.00	0.00	0.00	0.00	0.00	
X Profit/(Loss) for the period for dis-continued operation	2.04	29.31	7.74	48.23	47.07	
XI Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	
XII Profit/(Loss) for the period for dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	
XIII Profit/ (Loss) for the period (IX+XII)	0.00	0.00	0.00	0.00	0.00	
XIV Other Comprehensive Income	2.04	29.31	7.74	48.23	47.07	
A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
c) Other Comprehensive Income (net of tax)						
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	0.00	0.00	0.00	0.00	0.00	
XVI Paid-Up equity share capital (face value of Rs 10/- each)	2.04	29.31	7.74	48.23	47.07	
XVII Reserves (Excluding Revaluation Reserve)	1627.38	1627.38	1627.38	1627.38	1627.38	



XVIII	Earnings per equity shares (for continuing operation):					
	(1) Basic (Rs)	0.01	0.18	0.05	0.30	0.29
	(2) Diluted (Rs)	0.01	0.18	0.05	0.30	0.29


- The above results for the Quarter and financial year ended March 31, 2019 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 30/05/2019. The above results have been audited by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The figures for the quarter ended 31st March 2019 and 31st March 2018 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter.
- The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
 - Pharma Product
 - Chemicals Division
 - Plastic Division
- The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors
- The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- Ind AS 115- Revenue from Contracts with Customers, mandatory for reporting period beginning on or after 1st April, 2018 replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 1st April, 2018. Also the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related item in the financial results of the Company.

Date : 30/05/2019
Place : Indore

FOR Biofil Chemicals and Pharmaceuticals Limited




RAMESH SHAH
MANAGING DIRECTOR
(DIN: 00028819)




BIOFIL CHEMICALS AND PHARMACEUTICALS Ltd.
AUDITED FINANCIAL STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2019
CIN L24233MP1985PLC002709

Particulars	(Amount in Lakhs)	
	As at 31/03/2019	As at 31/03/2018
A ASSETS		
1 Non-current assets:		
(a) Property, Plant & Equipment	1,029.420	924.682
(b) Capital work in Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible assets	-	-
(f) Intangible Assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financial Assets:		
i. Investments	-	-
ii. Trade receivables	-	-
iii. Loans	-	-
(i) Deferred tax assets (net)	-	-
(j) Other Non- Current Assets	-	-
Sub-total - Non-current assets	1,029.420	924.682
2 Current assets		
(a) Inventories	119.092	102.484
(b) Financial Assets:		
(i) Investment	-	-
(ii) Trade receivables	-	-
(iii) Cash and cash equivalents	1,202.501	1,298.082
(iv) Bank balances other than (iii) above	5.640	10.712
(v) Loans	7.978	26.739
(vi) Others (to be specified)	-	-
(c) Current Tax Assest (Net)	-	-
(d) Other Currents Assets	56.672	52.770
Sub-total - Current assets	1,391.882	1,490.788
TOTAL - ASSETS	2,421.302	2,415.470
B EQUITY AND LIABILITIES		
1 Equity		
(i) Equity Share Capital	1,627.380	1,627.380
(ii) Other Entity	(262.411)	(310.645)
Sub-total- Equity	1,364.969	1,316.735
2 Liabilities		
Non-current Liabilities :		
a. Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(a) total outstanding dues of micro enterprises and small enterprises; and	-	-
than micro enterprises and small Enterprises.]	-	-
(iii) other Financial Liabilities	-	-
b. Provisions	-	-
c. Deferred tax liabilities (net)	-	-
d. Other Non-current Liabilities	-	-
Sub-total - Non-current liabilities	1,364.969	1,316.735
3 Current liabilities		
a. Financial Liabilities		
(i) Borrowings	163.731	155.855
(ii) Trade Payables :-		
(a) total outstanding dues of micro enterprises and small enterprises; and	-	-
than micro enterprises and small Enterprises.]	-	-
(iii) other Financial Liabilities	858.341	914.169
b. Other Current Liabilities	22.750	17.411
c. Provisions	-	-
d. Current Tax Liabilities (Net)	11.511	11.300
Sub-total - Current liabilities	1,056.333	1,098.735
TOTAL - EQUITY AND LIABILITIES	2,421.302	2,415.470

Date: 30/05/2019
Place: INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

RAMESH SHAH
 MANAGING DIRECTOR
 (DIN 00028819)



BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.
CIN L24233MP1985PLC002709

Segmentwise Revenue, Results and Capital Employed for year ended 31st March -2019

S.No.	Segment Revenue	(Amount in Lakhs)				
		Quarter Ended			Year Ended	
		March 31 , 2019 Audited	December 31, 2018 Reviewed	March 31 , 2018 Audited	31 March 2018 Audited	31 March 2019 Audited
1	Segment Revenue					
	Pharma Unit					
	Chemicals Division	200.90	1,379.95	301.03	1,053.13	2,110.13
	Plastic Division	46.55	49.45	54.14	180.02	202.73
	Other	0.00	0.00	0.00	2.84	0.00
	Gross Turnover	2.30	2.02	5.37	10.07	7.98
		249.75	1,431.42	360.55	1,246.07	2,320.84
2	Segment Results					
	Pharma Unit					
	Chemicals Division	27.80	18.19	30.78	56.31	63.52
	Plastic Division	(4.53)	15.00	(6.55)	26.91	22.36
	Other	1.25	0.00	4.40	(4.01)	(3.69)
		(8.45)		(8.41)	(8.41)	(8.45)
	Total Segment Profit Before Tax	16.07	33.19	20.22	70.79	73.72
	Interest Income					
	Interest Expenses	2.14		3.03	3.03	2.14
	Other Unallocable Income net of Expenditure	4.57	3.88	3.75	15.00	16.03
	Profit Before Tax	13.63	29.31	19.49	58.82	59.83
	Provision for current tax					
	Item Related Earlier Year	11.51	0.00	11.30	11.30	11.51
	Profit After Tax	2.04	29.31	7.75	47.07	48.23
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division					
	Chemicals Division	1,411.31	2,378.71	1,485.86	1,485.86	1,411.31
	Plastic Division	958.88	914.37	866.71	866.71	958.88
	Other	51.11	60.45	62.89	62.89	51.11
	Total (A)	2,421.29	3,353.52	2,415.46	2,415.46	2,421.29
	Segment Liabilities (B)					
	Pharma Division					
	Chemicals Division	792.75	1,815.79	898.26	898.26	792.75
	Plastic Division	98.00	35.65	41.52	41.52	98.00
	Other	165.58	169.52	158.96	158.96	165.58
	Total (B)	1,056.33	2,020.96	1,098.74	1,098.74	1,056.33
	Total Capital Employed (Segment Assets- Segment Liabilities)					
	Pharma Division					
	Chemicals Division	618.55	562.92	587.60	587.60	618.55
	Plastic Division	860.88	878.72	825.19	825.19	860.88
	Other	(114.48)	(109.07)	(96.07)	(96.07)	(114.48)
	Total Capital Employed (Segment Assets- Segment Liabilities)	1,364.96	1,332.57	1,316.73	1,316.73	1,364.96

DATE : 30/05/2019
PLACE : INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.


RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819





Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited

We have audited the quarterly financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the quarter ended on 31st March, 2019 and the year to date results for the year from 1st April, 2018 to 31st March, 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standards for Interim Financial Reporting (Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as year to date financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2019 as well as year to date results for the year from 01st April, 2018 to 31st March 2019.

For Maheshwari & Gupta
Chartered Accountant

CA Sunil Maheshwari
Partner
M No.403346

Place: Indore
Date: 30.05.2019





BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 30/05/2019

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	--

Sub: Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company for the year ended 31st March, 2019 as per second proviso to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

DECLARATION

Pursuant to Regulation 33(3)(d) of **SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**, I, the undersigned do hereby declare that in the Audit Report accompanying the Annual Audited Financial Statements of **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** for the financial year ended on **31st March, 2019**, the Statutory Auditor M/s Maheshwari & Gupta did not express any modified opinion/audit qualification or other reservation and accordingly, the Statement on Impact of Audit Qualifications is not required to be given.

You are requested to please consider and take on record the same.

Thanking You,

Yours Faithfully,

For Biofil Chemicals and Pharma. ceuticals Limited


Ramesh Shah
Managing Director
DIN: 00028819

